Tourmaline Bio, Inc.

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. The company develops pacibekitug, a long-acting, fully human, anti-IL-6 antibody with best-in-class potential and differentiated properties including a naturally long half-life, low immunogenicity and high binding affinity to IL-6. It develops medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was incorporated in 2002 and is based in New York, New York. As of September 9, 2025, Tourmaline Bio, Inc. operates as a subsidiary of Novartis AG.